Compare Charles River Laboratories Intl. Inc (CRL) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Expeditors International of Wshngtn Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $284.6 (market cap $13.46B), while Expeditors International of Wshngtn Inc trades at $180.07 (market cap $23.04B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | EXPD | |
|---|---|---|
Market Cap | $13.46B | $23.04B |
Sector | Health | Industrials |
52-Week High | $282.00 | $182.80 |
52-Week Low | $145.57 | $113.13 |
Enterprise Value | $16.30B | $22.57B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
EXPD trades at $179.00, near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $2.03 per share, beating estimates by 20%, driven by airfreight and customs demand. Revenue growth is steady, with 2026 projected at $12.0B, though ocean freight contraction poses a headwind. Analyst consensus is a Hold with a $181.14 price target, indicating limited near-term upside.
Outlook: EXPD's earnings momentum and expanding AOG services offer growth potential, but high valuation (P/E 25.79) and reliance on tariff policies heighten risk. Investors should weigh robust profitability (ROE 42.6%) against cyclical freight pressures and analyst caution. The stock is fairly valued, with gains contingent on sustaining airfreight strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
